AUSTIN, Texas , Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor , President and Chief Executive Officer of Rein Therapeutics , will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9, 2026 , at 11:00 a.m. ET . A live webcast of the presentation may be accessed via the Investors section of the Rein website at ir.reintx.com . An archived replay of the event will be available on the website for approximately 90 days following the conference. About Rein Therapeutics Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received both Orphan Drug and Fast Track designations in the U.S. Investor Contact IR@ReinTx.com Source: Rein Therapeutics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.